C
Dynavax Technologies Corporation DVAX
$12.68 -$0.17-1.32%
Recommendation
Hold
Prev Close
$12.85
Volume
752,785
Avg Vol (90D)
1,969,316
Market Cap
$1.59B
Dividend & Yield
--
52-Week Range
$9.74 - $14.63
P/E (TTM)
72.52
EPS (TTM)
$0.1772
My Lists My Alerts
Rating
Reward
C+
Fair
Risk
D+
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Good
Solvency Index
Excellent
Total Return Index
Fair
Volatility Index
Fair
Dividend Index
--
Headlines
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
4/4/2025 - Zacks Investment Research
Dynavax Files Preliminary Proxy Statement
4/3/2025 - PR Newswire
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
4/3/2025 - Zacks Investment Research
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up
4/3/2025 - Zacks Investment Research
Dynavax Technologies (DVAX, $12.87) RSI Indicator left the oversold zone on April 02, 2025
4/3/2025 - Tickeron - Stocks
AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol
4/2/2025 - Zacks Investment Research
Dynavax Technologies (DVAX, $12.71) RSI Indicator left the oversold zone on April 01, 2025
4/2/2025 - Tickeron - Technical Analysis
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates
4/1/2025 - Zacks Investment Research
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
4/1/2025 - Zacks Investment Research
Dynavax Technologies (DVAX, $12.97) Stochastic Oscillator left the oversold zone on March 31, 2025
4/1/2025 - Tickeron - Technical Analysis
Dynavax Technologies (DVAX, $12.97) price exceeded its 50-day Moving Average on March 31, 2025
4/1/2025 - Tickeron - Technical Analysis
Dynavax Technologies (DVAX, $12.97) price may climb as it broke lower Bollinger Band on Mar 31, 2025
4/1/2025 - Tickeron - Technical Analysis
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus
3/28/2025 - Zacks Investment Research
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance
3/28/2025 - Zacks Investment Research
Blair William & Co. IL Has $28.88 Million Stake in Dynavax Technologies Co. (NASDAQ:DVAX)
3/28/2025 - Ticker Report
Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma
3/27/2025 - Zacks Investment Research
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
3/27/2025 - Zacks Investment Research
Dynavax Technologies Target of Unusually Large Options Trading (NASDAQ:DVAX)
3/26/2025 - MarketBeat
Dynavax Technologies (DVAX, $13.98) Stochastic Oscillator left the oversold zone on March 25, 2025
3/26/2025 - Tickeron - Technical Analysis
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?
3/25/2025 - Zacks Investment Research
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
3/25/2025 - Zacks Investment Research
Advantage Alpha Capital Partners LP Cuts Stake in Dynavax Technologies Co. (NASDAQ:DVAX)
3/25/2025 - Ticker Report
Advantage Alpha Capital Partners LP Sells 21,053 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)
3/25/2025 - MarketBeat
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
3/24/2025 - Zacks Investment Research
First Week of DVAX May 16th Options Trading
3/24/2025 - Stock Options Channel
Income Statement
Total Revenue (TTM)
$277.25M
EBITDA (TTM)
$5.52M
EBIT (TTM)
$893.00K
Net Income (TTM)
$27.31M
Balance Sheet
Total Assets (Q)
$986.26M
Total Debt (Q)
$254.42M
Total Liabilities (Q)
$389.46M
Book Value Per Share (Q)
$4.76
Cash Flow
Cash from Operations (TTM)
$66.51M
Cash from Investing (TTM)
-$18.04M
Cash from Financing (TTM)
-$102.02M
Net Change in Cash (TTM)
-$54.40M
Filings
Filing Date
Thursday, February 20, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
0.53
7-Day Total Return
-6.63%
30-Day Total Return
-4.88%
60-Day Total Return
-1.17%
90-Day Total Return
2.59%
Year to Date Total Return
-1.71%
1-Year Total Return
4.97%
2-Year Total Return
28.73%
3-Year Total Return
9.69%
5-Year Total Return
290.15%
52-week Low
Aug 06, 2024 - $9.74
52-week High
Mar 07, 2025 - $14.63
Valuation
Market Cap
$1.59B - Small Cap
Enterprise Value
$1.13B
Price/Sales (TTM)
7.09
Price/Book (Q)
2.70
Dividends and Shares
Shares Outstanding
153.02M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.dynavax.com
Phone Number
510 848 5100
Address
2100 Powell Street
EmeryVille, CA 94608
Country
United States
Year Founded
1996
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers... more
NASDAQ 04/04/2025 12:38PM Eastern Quotes delayed
Weiss Ratings